Equities analysts expect CytomX Therapeutics, Inc. (NASDAQ:CTMX) to post $17.27 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for CytomX Therapeutics’ earnings, with the highest sales estimate coming in at $23.30 million and the lowest estimate coming in at $13.50 million. CytomX Therapeutics posted sales of $3.45 million in the same quarter last year, which suggests a positive year-over-year growth rate of 400.6%. The business is expected to report its next quarterly earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that CytomX Therapeutics will report full-year sales of $17.27 million for the current year, with estimates ranging from $36.00 million to $53.10 million. For the next fiscal year, analysts forecast that the company will report sales of $66.20 million per share, with estimates ranging from $40.00 million to $104.60 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.30). The business had revenue of $8.75 million for the quarter, compared to analyst estimates of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%.

Several equities analysts have weighed in on the company. BidaskClub upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. Nomura lifted their target price on CytomX Therapeutics to $44.00 and gave the stock a “buy” rating in a report on Wednesday. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday. Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a research note on Tuesday, August 8th. Finally, Bank of America Corporation reissued a “buy” rating and set a $30.00 price target (up from $28.00) on shares of CytomX Therapeutics in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $32.67.

Shares of CytomX Therapeutics (CTMX) traded up 21.53% during mid-day trading on Wednesday, hitting $23.09. 3,353,455 shares of the stock were exchanged. The stock’s 50 day moving average price is $16.92 and its 200-day moving average price is $15.62. CytomX Therapeutics has a 12-month low of $9.85 and a 12-month high of $24.67. The stock’s market capitalization is $851.26 million.

In other news, major shareholder Robert I. Tepper sold 24,777 shares of the business’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $24.34, for a total value of $603,072.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sean A. Mccarthy sold 4,781 shares of the business’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $15.00, for a total value of $71,715.00. Following the completion of the transaction, the insider now directly owns 9,026 shares of the company’s stock, valued at $135,390. The disclosure for this sale can be found here. Over the last three months, insiders sold 90,744 shares of company stock valued at $1,747,180. Corporate insiders own 8.00% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. EcoR1 Capital LLC purchased a new position in CytomX Therapeutics during the 1st quarter worth $13,729,000. Numeric Investors LLC purchased a new position in CytomX Therapeutics during the 2nd quarter worth $9,730,000. Perceptive Advisors LLC grew its stake in CytomX Therapeutics by 65.7% during the 1st quarter. Perceptive Advisors LLC now owns 1,530,659 shares of the biotechnology company’s stock worth $26,434,000 after buying an additional 606,896 shares during the last quarter. Driehaus Capital Management LLC purchased a new position in CytomX Therapeutics during the 1st quarter worth $5,089,000. Finally, State Street Corp grew its stake in CytomX Therapeutics by 58.8% during the 2nd quarter. State Street Corp now owns 446,315 shares of the biotechnology company’s stock worth $6,914,000 after buying an additional 165,342 shares during the last quarter. 59.97% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/04/cytomx-therapeutics-inc-ctmx-expected-to-post-quarterly-sales-of-17-27-million.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.